The structural part of the hepatitis C virus (HCV) genome encodes a capsid protein, C, and two envelope glycoproteins, E1 and E2, released from the virus polyprotein precursor by signalase(s) cleavage(s). The processing of E1 was investigated by infecting simian cells with recombinant vaccinia viruses expressing parts of the HCV structural proteins. When the predicted E1 sequence was expressed alone (amino acid residues 174-370 of the polyprotein) or with the capsid protein gene (residues 1-370), it showed an apparent molecular mass of 35 kDa as measured by SDS-PAGE analysis. However, when E1 was expressed as part of a truncated C-El-truncated E2 polypeptide (residues 132-383), the processed E1 product had the expected apparent molecular mass of 31 kDa, suggesting that flanking sequences are necessary for the generation of the mature 31 kDa E1 form. The N-terminal sequence of the two E1 forms was found to be the same. Analysis of the glycosylation pattern showed that, in both species, only four of the five potential N-linked glycosylation sites were recognized, indicating that glycosylation was not involved in the molecular mass difference. We showed that expression of E1 with or without the hydrophobic stretch of amino acids residues 371-383, defined as the E2 signal sequence, may be responsible for the difference in electrophoretic mobility of the two E1 species. In vitro translation assays and site-directed mutagenesis experiments suggest that this sequence remains part of the 31 kDa E1 mature protein.
Introduction
Hepatitis C virus (HCV) has been identified as the principal agent of parenterally transmitted non-A, non-B hepatitis (Choo et al., 1989; Kuo et al., 1989) . Comparative analyses of the genomes of several HCV strains (Chen et al., 1992; Choo et al., 1991; Inchauspe et al., 1991; Kato et al., 1990; Okamoto et al., 1991; Takamisawa et aI., 1991) indicate that HCV is a member of the family Flaviviridae, which includes flaviviruses and pestiviruses (Francki et al., 1991) . It has a 9"5 kb ssRNA genome of positive polarity with a unique open reading frame coding for a 3011 amino acid polyprotein. The HCV gene order has been determined as 5' C-E1-E2-p7-p23-NS3-NS4A-NS4B-NS5A-NS5B 3' (Bartenschlager et al., 1993; Grakoui et al., 1993a; Manabe et aL, 1994; Tomei et al., 1993) . The non-structural proteins are processed by two virus proteinases, p23 and NS3 (Bartenschlager et al., 1993; Grakoui et al., 1993a, b Hijikata et al., 1993; Manabe et al., 1994; Tomei et al., 1993) , whereas processing of the capsid protein (C) and the two membrane-associated glycoproteins E1 and E2 is mediated by host signalase(s) (Grakoui et al., 1993c; Hijikata et al., 1991) .
Analysis of the location of the cleavage sites between structural proteins is based on determination of the Nterminal amino acid sequences of E1 and E2. The first amino acid residue of E1 has been identified as Tyr '92 (Hijikata et al., 1991) and the first residue of E2 as His 3s~ (Hijikata et al., 1991) or Glu 384 (Lin et al., 1994) , depending on the isolate. E1 and E2 are both preceded by hydrophobic segments (residues 174-191 and 371-383 of the polyprotein, respectively) that may be considered as signal sequences. The E2 protein seems to display a complex processing consistent with the generation of multiple E2 species (Lin et al., 1994; Mizushima et al., 1994) and forms a stable complex with E1 which is coimmunoprecipitable (Dubuisson et al., 1994; Grakoui et al., 1993c; Lanford et al., 1993; Ralston et al., 1993) . Little is known about the processing of E1 and the requirements in cis of capsid protein and E2 sequences on its release. The apparent molecular mass of E1 is not accurately known. It varies from 28 to 35 kDa depending upon the strain and the conditions of expression
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A. Fournillier-Jacob and others (Grakoui et al., 1993c; Hijikata et al., 1991 ; Lanford et al., 1993; Matsuura et al., 1992; Ralston et al., 1993) . The exact molecular characteristics of the structural proteins in the HCV virion are not known, because a cellular system allowing virus propagation is still unavailable.
In this report, we examined the processing of the E 1 glycoprotein of HCV Hutchinson (H) strain expressed from recombinant vaccinia viruses. The expression of the entire structural region generated a 31 kDa E1 glycoprotein, whereas the expression of the predicted E1 sequence alone generated an unexpected 35 kDa product. The processing at the N terminus and the number of glycosylated residues of these two E1 species were identical. The occurrence of the 31 kDa mature form of E1 was dependent on whether E1 was produced from a polyprotein precursor containing the E2 signal peptide and part of E2 or part of the capsid protein. Our data indicate that the hydrophobic signal sequence of E2, which probably remains attached to the mature form of El, is responsible for the difference in electrophoretic mobility of the two E1 species and that the last amino acid of E1 may be considered as residue Ala as3.
Methods
Cell cultures and viruses. Cell lines [CV1, HeLa and human 143B thymidine kinase-deficient (tk) cells] were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL) supplemented with 5 % fetal calf serum (FCS), penicillin (100 units/ml) and streptomycin (100 lag/ml). The wild-type vaccinia virus Copenhagen strain and its thermosensitive ts7 derivative (Drillien et al., 1982) were cultivated on HeLa cells, purified on sucrose gradients and titrated on CV1 cells. Virus vTF7-3, a vaccinia virus recombinant expressing the T7 DNAdependent RNA polymerase (Fuerst et al., 1986) , was obtained from B. Moss (National Institutes of Health, Bethesda, Md., USA).
Molecular cloning of the HCV genome.
A cDNA clone of the HCV genome was generated from the liver of a chimpanzee infected with the H strain of HCV (Feinstone et al., 1981) . Briefly, RNA purified by caesium trifluoroacetate isopycnic centrifugation (Zarlenga & Gamble, 1987) was used as a template for cDNA synthesis (Giibler & Hoffman, 1983) with primers based on the published HCV cDNA sequence (Choo et al., 1991) . Double-stranded cDNA was PCR-amplified using a standard procedure (Saiki et al., 1988) and inserted into the SmaIlinearized and dephosphorylated vector pGEM-3Zf(+) (Promega). Utilizing partial sequence data and restriction enzyme mapping, a clone containing the entire ORF, called pG/HCV1-9428, was then assembled (C. Wychowski and S. M. Feinstone, unpublished results) .
pTM1 plasmid constructs and generation of recombinant vaccinia viruses. Fragments encoding HCV structural proteins were PCRamplified from pG/HCV1-9428. The resulting DNAs were inserted into the pTM 1 polylinker (Moss et al., 1990) . pTM 1 contains an unique NcoI restriction site aud a polycloning region immediately downstream of the T7 promoter and the encephalomyocarditis virus internal ribosome entry site for cap-independent translation initiation. Recombinant DNA manipulations were made according to standard methods (Sambrook et al., 1989) . Recombinant plasmids were checked by sequencing as described (Sanger et al., 1977) . The constructs used for expression of HCV proteins are summarized in Table 1 . The two mutant plasmids E1-V37°-E2174_616 and E1-R383-E2174_616, derived from the pTM1 plasmid El-E2174_61 ~, were prepared by PCR using primers carrying the corresponding mutated codons.
Recombinant vaccinia viruses were generated by homologous recombination essentially as described (Kieny et al., 1984) and plaque purified twice on 143B tk-cells under bromodeoxyuridine selection (50 gg/ml). Each virus stock, derived from a single plaque isolate, was expanded in HeLa cells at a m.o.i, of 1 p.f.u./cell.
In vitro transcription and translation. DNA from purified recombinant pTM1 plasmids (2 lag) was used as template for in vitro transcription with T7 RNA polymerase (Promega). After a 60 min incubation at 37 °C followed by a 15 min RNase-free DNase RQI treatment (1 unit/lag), RNAs were extracted with phenol-chloroform and ethanol-precipitated. Purified RNA transcripts were used at a concentration of 100 lag/ml for in vitro translation reactions using a rabbit reticulocyte lysate (Promega) supplemented with 151aCi [~S]methionine (Amersham) in the presence or absence of canine pancreatic microsomal membranes. After 60 min at 30 °C, samples were heated at 100 °C for 5 min in the presence of Laemmli buffer. Cellfree translation protein products were analysed by SDS PAGE.
Vaccinia virus expression assays and protein analyses. CV1 cells were infected with vTF7-3 alone or in combination with recombinant vaccinia viruses, each at a m.o.i, of 5 p.f.u./cell. After 1 h at 37 °C, the inoculum was removed and replaced with DMEM supplemented with 5 % FCS. At 12 h post-infection, the cells were incubated for 2 h with DMEM minus methionine and then labelled for 3 h with 50 laCi/ml [35S]methionine. The labelled cells were lysed in 50 mM-Tri~HC1 pH 7.5, 150 mM-NaC1, 1 mM-EDTA, 1% NP40 and 10 lag/ml aprotinin. HCV-specific proteins were immunoprecipitated from the clarified radiolabelled lysates using rabbit anti-HCV antisera obtained according to Cahour et al. (1992) ; the sera will be described elsewhere (A. Fournillier-Jacob, A. Cahour, N. Escriou, M. Girard and C. Wychowski, unpublished results) . Immunoprecipitation was carried out as described (Wychowski et al., 1985) and the immunoprecipitates were analysed by SDS-PAGE. Gels were fixed, dried and subjected to autoradiography.
Tunicamycin treatment and endoglycosidase reactions. For tunicamycin treatment, CV1 cells were infected and labelled as described above, except that tunicamycin (5 lag/ml; Boehringer Mannheim) was added to the medium at 12 h post-infection until the end of the labelling period. Digestions with endoglycosidase H (Boehringer Mannheim) were performed on immunoprecipitated radiolabelled glycoproteins. After immunoprecipitation, Protein A-Sepharose-bound immune complexes were eluted with 0.2 % SDS and 1% 2-mercaptoethanol (2-ME), heated for 20 rain at 65 °C and spun down for 10 rain at 10000g. Supernatants were adjusted to 50 mM-sodium acetate pH 5.5, 50 mN-EDTA, 1% NP40, 0"1% SDS, 1% 2-ME and 1 mM-PMSF and incubated at 37 °C with different amounts of endoglycosidase H for either 10 min (partial digestion) or overnight (complete digestion). Thereafter, five volumes of cold acetone were added. The precipitates were pelleted by centrifugation, denatured for 5 min in Laemmli sample buffer and submitted to electrophoresis.
N-terminal sequence analysis. CV1 cells, co-infected with vTF7-3 and vv/C-Ell aT0 as described above, were washed at 1 h post-infection with DMEM lacking the amino acid used for the radiolabelling and labelled for 16 h with 250 laCi/ml of either [3HJleucine or [3H]arginine. After labelling, the infected cells were lysed as described and the clear lysates were immunoprecipitated with rabbit anti-E1 serum. Digestion with peptide N-glycosidase F (PNGase F) was for 1 h at 37 °C in the buffer provided by the manufacturer (New England Biolabs). The digested products were fractionated by SDS-PAGE, electroblotted onto nitrocellulose membranes (Hybond C; Amersham) and detected by autoradiography. Radiolabelled products were excised and subjected to partial amino acid sequence analyses performed by sequential Edman degradation on an Applied Biosystems 473 A gas-phase sequencer. Acetonitryl-containing fractions were dried and counted in a scintillation counter.
Results

Expression of HCV E1 and E2 glycoproteins
To study the maturation of El, we used recombinant vaccinia viruses expressing some or all of the HCV structural proteins (Table 1) . Five recombinant vaccinia viruses ( Fig. la) were first compared: vv/C-E1-E2-P71-s09, vv/E1-E2174 741, v v / E 2 -p 7 a 7 1 s09, vv/E1174 a70 a n d vv/C-Ell_a70. Radiolabelled lysates of CV1 cells infected with T7 RNA polymerase-expressing vaccinia virus vTF7-3 and each of the recombinant vaccinia viruses were immunoprecipitated with El-or E2-specific rabbit antiserum. The expression of vv/C-E1-E2-p71 809 gave rise to two proteins that reacted with the anti-E1 serum (Fig. lb , lane 2): a 31 kDa E1 product as described before (Grakoui et al., 1993 c) and a 73 kDa protein. The latter co-migrated with the unprocessed E2-p7 polypeptide ( Fig. 1 b, lane 4) and probably resulted from the coprecipitation of E1/E2-p7 complexes. Co-precipitation of the El/E2 glycoproteins was also observed when using an E2-specific serum (data not shown). By contrast, the expression of vv/C-E11 370 gave rise to an E1 product which migrated with an apparent molecular mass of about 35 kDa ( Fig. 1 b, lane 6 ). The molecular mass of E1 generated from w/Ell7 ~ 270, which corresponds to its predicted sequence according to the hydropathicity profile, was also about 35 kDa ( Fig. 1 b, lane 5). However, E1 generated from vv/E1-E2_ 741 had a molecular mass of 31kDa ( migration of the mixed immunoprecipitated products of vv/E1-E2m 741 and vv/C-E11_370 resulted in both the 31 and 35 kDa bands (data not shown). These results suggest that the 31 kDa protein represents the mature HCV E1 glycoprotein, as expressed with this system, whereas the 35 kDa species, expressed from a gene coding for the predicted E1 sequence, represents an immature E1 glycoprotein.
N-terminal sequence analysis
To determine if the unexpected 35 kDa E1 species resulted from a lack of cleavage of the E1 signal peptide, we sequenced the N terminus of the protein.
[3H]leucineor [3H]arginine-labelled lysates were prepared from CV1 cells co-infected with vTF7-3 and vv/C-E11 aT0-Samples were immunoprecipitated with anti-E1 serum and digested with PNGase F. This endoglycosidase was used because a digestion time of 1 h provides suitable material for N-terminal sequence analysis (Lin et al., 1994) . The deglycosylated form of the 35 kDa product was separated by SDS-PAGE, transferred onto a nitrocellulose membrane and sequenced through 10 cycles of Edman degradation. As shown in Fig. 2 , an arginine residue was detected at position 4 and a leucine residue at position 9. This is consistent with the sequence shown in Fig. 2 where Tyr 192 is the N-terminal residue of the E1 glycoprotein, as reported for the HCV J (Hijikata et al., 1991) and HCV H (Lin et al., 1994) strains. This result therefore shows that the N terminus of the 35 kDa product is identical to that of the 31 kDa product and that the E1 signal peptide is correctly trimmed from the 35 kDa E1 product.
Influence of glycosytation
To determine whether glycosylation could account for the difference in molecular mass between the two E1 species, partial digestion with endoglycosidase H was performed. Endoglycosidase H was used because it has been reported that HCV envelope proteins lack complex glycans (Dubuisson et al., 1994; Ralston et al., 1993) as shown in heterologous expression systems. A lysate of CV1 cells infected with vTF7-3 and vv/E1-E217~v41 , immunoprecipitated with rabbit anti-E1 serum, was digested with endoglycosidase H and analysed by SDS-PAGE (Fig. 3 a) . Partial digestion of E1 resulted in discrete deglycosylated E 1-specific bands migrating more rapidly than undigested E 1 (Fig. 3 a; compare lane 1 with lanes 2, 3 and 4). By increasing the concentration of endoglycosidase H, four new E1 species with molecular masses of 28.5, 26, 23 and 20 kDa were generated, suggesting that E1 contains only four N-linked oligosaccharide chains, although there are five potential Nlinked glycosylation sites in its sequence. Four new species were also obtained when partial endoglycosidase H analysis was performed on the 35 kDa E1 species expressed by vv/E1174_370 (data not shown). The analysis of the deglycosylation pattern of E2 was more complex (Fig. 3 a) and has not been clearly defined. Cells infected with vv/E1-E2174_741 or vv/C-E11_370 and labelled in the presence of tunicamycin yielded deglycosylated proteins with molecular masses of 19 and 23 kDa, respectively (Fig. 3 b, lanes 2 and 3) . Therefore, the difference of 4 kDa between the two forms of E1 persisted when the polypeptides were not glycosylated. The E1 glycoprotein obtained from cells infected by vv/E1-E2__74 a and treated with tunicamycin (Fig. 3a , lane 5) was observed to migrate faster than the deglycosylated protein produced by endoglycosidase H digestion (Fig. 3a, lane 4) . This discrepancy can be explained by the fact that the transfer of the core oligosaccharide structure to the polypeptide backbone is blocked by tunicamycin (Kornfeld & Kornfeld, 1985) , whereas endoglycosidase H digestion removes N-linked high-mannose-type glycans (Maley et al., 1989) , leaving one N-acetylglucosamine (Tarentino et aI., 1974) . Altogether, these results indicate that the difference in molecular mass of the E1 products was not due to differences in glycosylation.
Flanking sequences are required for efficient processing of E1
As expression of the El-E2 precursor seemed to be necessary for the generation of the mature 31 kDa E1 glycoprotein, we investigated the impact of the presence of E2 sequences on E1 processing. Recombinant vaccinia viruses that expressed polyproteins with progressive Cterminal truncations in E2 were constructed (Fig. 4a) . Cytoplasmic extracts were prepared from cells infected with these recombinants, immunoprecipitated with Elspecific antiserum and analysed by SDS-PAGE (Fig.  4b) . A 31 kDa E1 product was obtained when E1 was expressed along with full-length E2 (lane 2) or with E2 truncated at residue 616 (vv/E1-E2174_+l~; lane 3) or 524 (vv/E1-E2174 524; lane 4). However, when only the 13 amino acids corresponding to the predicted E2 signal peptide (vv/El__ 383) were present, the E1 glycoprotein m i g r a t i n g as a diffuse b a n d , r a n g i n g f r o m 32 to 34 k D a (lane 5), p r e s u m a b l y due to i n c o m p l e t e m a t u r a t i o n or i n c o m p l e t e folding. Cells infected with vv/El174_3s 3 a n d labelled in the presence of t u n i c a m y c i n also yielded a n E 1 p r o t e i n m i g r a t i n g as a diffuse b a n d (data n o t shown). O u r findings suggest that the presence of a m i n o acids d o w n s t r e a m f r o m the E2 signal peptide, such as residues 383 to 524, is required for the correct processing of E1 w h e n this p r o t e i n is expressed in the absence o f the capsid protein. W e also showed that c o -i m m u n op r e c i p i t a t i o n of E2 using anti-E1 s e r u m p r e s u m a b l y r e q u i r e d the entire sequence or at least m o r e t h a n the first 233 residues o f E2, as C -t e r m i n a l -t r u n c a t e d forms of E2 were n o t c o -i m m u n o p r e c i p i t a t e d with E l . As p r e v i o u s l y suggested (Selby et aI., 1994) , residues 617 to 741 of the H C V p o l y p r o t e i n m a y be necessary for E l -E 2 interaction.
T o d e t e r m i n e w h e t h e r the capsid p r o t e i n was involved in the processing of E l , r e c o m b i n a n t vaccinia viruses expressing the full-length capsid p r o t e i n or its 40 C- terminal amino acids (CA), followed by the sequences coding for E1 and various parts of E2, were generated. The 31 kDa form of E1 was obtained when E1 was expressed along with the C-terminal part of the capsid protein and the signal peptide of E2 (vv/CA-Elx3~ 383; Fig. 5, lane 3) . On the basis of these data, it appears that together the 40 C-terminal amino acid residues of the capsid protein and the signal peptide of E2 are sufficient for the generation of a 31 kDa E1 glycoprotein.
Influence of the E2 signal peptide on the electrophoretic mobility of E1
As the 31 and 3 5 k D a E1 species have the same N terminus and the same number of glycosylated residues, their molecular mass difference may be the result of different C termini. Possibly, a structural element, such as the hydrophobic stretch of amino acids of the E2 signal peptide, may alter the electrophoretic mobility of El. To determine whether this sequence (aa 371 to 383) could account for the molecular mass differences of the two E1 species, in vitro transcription-translation experiments were performed as described in Methods. Both E1 species were also observed in this system. The polypeptide synthesized from the recombinant pTM 1 plasmid Ellv4_3s 3 w a s compared to polypeptides similarly expressed in vitro from constructs reported above. Surprisingly, when expressed without microsomal membranes, the E1~74 88a product (Fig. 6a , lane 2) migrated faster on a S D S -P A G E gel than the E 1 a74-~o product (Fig. 6 a, lane   1 ). In the presence of microsomal membranes, the Elm_38 a product migrated as a diffuse band with a molecular mass between 32 and 3 4 k D a (Fig. 6b , compare lane 3 with lanes 2 and 4), which may be related to the results obtained in vivo when the El17 ~ 3sa polypeptide was expressed by recombinant vaccinia virus (Fig. 4b, lane 5) . Products migrating faster than the E1 proteins were observed (Fig. 6b) , which probably corresponded to incompletely glycosylated forms. In conclusion, the presence of the E2 signal peptide at the C terminus of the predicted sequence of E1 is able to increase the electrophoretic mobility of this protein and is probably responsible for the difference in molecular mass observed between the 31 and 35 kDa E1 species. It is possible that E1 protein migration in an in vitro translation assay without microsomal membranes may be altered due to possible interactions between the uncleaved signal peptide at its N terminus and E2 signal peptide at its C terminus. We thus constructed two recombinant plasmids allowing expression of E 1 without its signal peptide, either from residues 192 to 370 or from residues 192 to 383 (Table 1 ). The addition of the E2 signal peptide to the E1 protein also increased the electrophoretic mobility of E1 (Fig. 6e , compare lanes 1 and 2), which confirmed our previous data. Our results showed that the addition of microsomal membranes did not change the molecular mass of the El192_3s 3 product (Fig. 6 c, compare lane 2 and 4), suggesting that the E2 signal peptide is not cleaved by a signalase at the C terminus of El.
Analysis of the E2 signal sequence as part of the E1 glycoprotein
To support the hypothesis that the E2 signal peptide is only cleaved at the N terminus of E2 at the site Ala3S3/Glu TM, we introduced mutations at residues that were likely to be important for the release of this signal peptide. Upon alteration of the hydropathicity profile of this region, we expected to disturb signal peptide cleavage. The last hydrophobic amino acid of the E2 signal peptide (Ala 383) was changed to a charged arginine residue. As Lys 37° is the only conserved charged residue between two stretches of uncharged amino acids (residues 347 to 369 and E2 signal sequence), we also mutated this amino acid to prevent cleavage of the E2 signal peptide at this upstream site. Two mutant recombinant vaccinia viruses that expressed E1 and an N-terminal part of E2 were generated, with the charged residue Lys 37° changed to a hydrophobic valine residue (vv/E 1-V37°-E2m_616) or the hydrophobic residue Ala 383 replaced by a charged arginine residue (vv/E1-R383-E217~616). Cytoplasmic extracts were prepared from cells infected with these recombinants, immunoprecipitated with El-specific anti- serum and analysed by SDS-PAGE (Fig. 7) . The expression of vv/E1-R383-E2174_616 gave rise to a product which migrated with a molecular mass of about 75 kDa, corresponding to unprocessed polypeptide (Fig. 7, lane  2) . In contrast, the expression of vv/E1-V37°-E2174_616 resulted in a 31 kDa mature E1 product (Fig. 7, lane 3) . These results showed that mutation of the conserved residue Lys 37° did not affect the processing of the El-E2174616 precursor. In contrast, the change at position 383 blocked the cleavage of the El-E2 m 616 precursor, which indicates that Ala 3sa is important for efficient cleavage between Ala as3 and Glu 384. These results taken together suggest that the E2 signal peptide is only cleaved at the site Alaass-Glu3S~ and that this sequence is probably a part of the mature E1 protein.
Discussion
In spite of the lack of an efficient cell culture system to grow HCV, it is now well established that the processing of the structural proteins is mediated by host cellular signalase(s) that generate the capsid protein and the two envelope glycoproteins. The exact positions of the N and C termini of E2 have been elucidated (Lin et at., 1994; Mizushima et al., 1994) . In contrast, relatively little is known about the processing of E1 and only its N terminus has been determined (Hijikata et al., 1991; Lin et al., 1994) .
In this study, we showed that recombinant viruses expressing a polyprotein containing El, flanked by the E2 signal peptide and part of E2 or part of the capsid protein, gave rise to an E1 product with a molecular mass of 31 kDa, as expected for the mature glycoprotein (Dubuisson et al., 1994; Grakoui et al., 1993c) . In contrast, recombinant viruses expressing the predicted E1 sequence (residues 174 to 370 of the HCV polyprotein) generated a 35 kDa E1 product, and expression of the E1 sequence followed by the signal peptide of E2 (residues 174 to 383) generated a product which migrated as a diffuse band of 32 to 34 kDa. The 35 kDa form of E1 has also been observed in other laboratories using recombinant baculovirus or vaccinia virus expression systems and the existence of these various E1 species has been hypothesized to reflect different processing or different degrees of glycosylation (Lanford et al., 1993; Ralston et al., 1993) .
One hypothesis to account for the occurrence of the 35 kDa E1 species would be non-release of the signal peptide at the N terminus of El, which spans residues 174 to 191 of the HCV polyprotein. However, microsequencing of the 35 kDa E1 species established the N terminus of this molecule as Tyr 192, which has been identified as the N terminus of the E1 protein. The existence of the 35kDa E1 glycoprotein does not therefore result from a defect in processing at the N terminus.
Glycosylation of the 31 and 35 kDa E1 glycoproteins was analysed to determine whether differences in glycosylation could account for the difference in molecular mass of the two species. There are five potential N-linked glycosylation sites in the E1 sequence of HCV strain H (Inchauspe et aI., 1991) ; the number of sites utilized has not been reported. In this study, we showed that, upon partial deglycosylation with endoglycosidase H, only four of the five potential glycosylation sites were recognized, in both the 31 and 35kDa E1 species. Previous reports have shown that the HCV glycoproteins are not translocated beyond the cis Golgi (Dubuisson et al., 1994; Ralston et al., 1993) . Thus, the 35 kDa E1 species is unlikely to be the result of the acquisition of complex endoglycosidase H-resistant glycans. Moreover, the fact that upon treatment of infected cells with tunicamycin, the 31 and 35kDa E1 species were synthesized as 19 and 23 kDa unglycosylated E1 proteins, respectively, confirms that N-linked glycans are not involved in the molecular mass difference.
The fact that the 31 kDa E1 species was detected if the sequence coding for E1 was flanked by the 40 C-terminal amino acids of the capsid protein and the 13 amino acids of the signal peptide of E2 indicates that correct maturation of the E1 glycoprotein is dependent on the coexpression in cis of these proteins. These results could explain why expression of El17~383 polypeptide in both the in vitro translation system in the presence of microsomal membranes (Fig. 6b ) and in cells infected with the corresponding recombinant vaccinia virus vv/ El174_3, 3 (Fig. 4b) did not produce a mature E1 glycoprotein of 31 kDa but resulted in a diffuse band. Some interactions between the proteins might be necessary for the maturation or the folding of the E1 protein.
These effects are similar to those observed for the structural region of Japanese encephalitis virus, in which correct processing of the M and E proteins is dependent on coexpression in cis of Pre-M, E and NS1 (Konishi et al., 1991) . In addition, we showed that the presence of flanking sequences downstream from the E2 signal peptide (residues 383 to 524) is required for the maturation of El, when this protein is expressed in the absence of the capsid protein. This result suggests that the E2 protein, which is non-covalently associated with E1 in the endoplasmic reticulum (Dubuisson et al., 1994; Matsuura et al., 1994) , could participate in the maturation process of the E1 protein in the absence of the capsid protein.
As the C terminus of E1 has not been precisely defined, two hypotheses may be proposed to account for the mature 31 kDa E1 glycoprotein. Firstly, we cannot exclude the possibility that expression of the 31 kDa species may depend on an unknown cleavage at its C terminus. However, we found no evidence for a Cterminal fragment consistent with such a cleavage in an in vitro translation system. Moreover, the results of sitedirected mutagenesis do not indicate this possibility, if we assume that the hypothetical cleavage is not dependent on cleavage at the Ala383-Glu 38~ site. As a second hypothesis, the presence at the E1 C terminus of the E2 signal peptide, composed mostly of hydrophobic leucine and valine residues, could be responsible for the difference in electrophoretic mobility observed between the two E1 species. Indeed, in vitro expression of E1 followed by the E2 signal peptide (El174_3s3) in the absence of microsomal membranes resulted in an E1 protein that migrated surprisingly faster than E 1 without this sequence (Fig. 6) . The processing of HCV structural proteins by signal peptidase raised the possibility that the hydrophobic signal sequence responsible for initiating translocation of the E2 envelope protein could remain part of the E1 protein. We observed that addition of microsomal membranes did not change the molecular mass of El192_383 (Fig. 6c) , which suggests that the E2 signal peptide is not cleaved by a signalase at the C terminus of El. Moreover, the fact that mutation of the conserved charged residue Lys 37° to a hydrophobic valine residue did not affect the cleavage of an El-E2 polyprotein precursor supports this hypothesis. Our results suggest that the E2 signal peptide is only cleaved at Ala383-Glu 38~ and that this sequence is still part of the mature E1 protein. In this respect, HCV would be quite similar to rubella virus, in which the second encoded envelope protein E1 signal peptide remains attached to the preceding E2 protein after processing (Baron et al., 1992) . In conclusion, the C-terminal amino acid residue of the E1 glycoprotein may be considered as Ala 3sa. However, determination of the C-terminal amino acid sequence of E1 needs to be completed for confirmation.
Altogether, these data demonstrate the importance of the selected cDNA sequence to get optimum expression of E 1 envelope glycoprotein, which may be useful for future research axes such as envelope interaction studies and diagnosis of HCV infection.
